The company reported a 10.6% year-on-year growth in its net profit at ₹1,378.9 crore in the December quarter of FY24 as against ₹1,237.90 crore in the corresponding period of the previous fiscal year.
In the past one month, six months and one year, the counter has given 0.49%, 16.77% and 23.70% in returns, respectively.
In the January to March period, the company's revenue from operations surged double-digit by 16% year-on-year (YoY) to ₹6,296.8.2 crore, up from ₹5,436.8 crore in the same period last year.
The portfolio includes 45 commercial products, four pipeline products and 40 approved non-marketed products, including many generic products, focused on women’s health
The Indian production facility of Mondelez, Dr. Reddy’s, and Cipla have joined WEF's Global Lighthouse Network
The Sensex and Nifty are set to open higher on the first day of September F&O contracts, tracking firm cues from global equities and positive trends on SGX Nifty Futures.
Dr. Reddy’s Laboratories has received the U.S. FDA approval to launch Fesoterodine Fumarate extended-release tablets in the American market
Revenue of the pharma company rose 15% year-on-year to ₹5,437 crore in the fourth quarter.
The BSE Sensex and the NSE Nifty are poised to open lower on Wednesday amid mixed global cues as well as growing Covid-19 cases surge across the country.
The healthcare sector is dominated by family-run firms, some of which have come into prominence in the past year.
